{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-007929","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.723869+00:00","generated_at":"2026-05-30T00:53:56.275699+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xenetic Q3 net loss $0.4M, R&D down 64% to $0.4M, cash $6.8M; advancing DNase platform toward Phase 1","bullets":["Net loss of $0.4M for Q3 2024; no material revenue reported.","R&D expenses fell 63.9% YoY to $0.4M from $1.0M due to lower process development spending.","Cash and equivalents were $6.8M at September 30, 2024.","Preclinical data for DNase I combination therapies in colorectal cancer models completed; presented at SITC 2024.","Strategic focus on institutional partnerships with Tokyo Medical University and Scripps Research Institute."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-007929","json":"https://secwatch.observer/filing/0001683168-24-007929.json","markdown":"https://secwatch.observer/filing/0001683168-24-007929.md","text":"https://secwatch.observer/filing/0001683168-24-007929.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824007929/0001683168-24-007929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824007929/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:53:56.275699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}